IBC’s Latest Updates: Weight Loss Drug Policy

The International Benefits Consortium (IBC) has recently revamped its weight management medication coverage, responding to the FDA’s approval of Zepbound—a potent combination of GIP and GLP-1 receptors. This aligns Zepbound with existing options like Wegovy® and Saxenda® under IBC’s coverage criteria. Key Points: Weight Loss Drug Policy Update: IBC’s weight loss drug policy now includes Zepbound, showcasing their commitment to staying current with pharmaceutical advancements and ensuring robust coverage options for members. CAA Gag Clause Attestation: Addressing transparency concerns, IBC acknowledges the CAA’s impact on healthcare communication by eliminating “gag clauses” that restrict information exchange between providers and patients. Healthy You Program Options: IBC introduces new program options for self-funded… Read More

Continue Reading

House Passes Health Care Transparency Law

In a significant move towards increased transparency and cost reduction in the healthcare sector, the U.S. House of Representatives voted 320-71 to pass the Lower Costs, More Transparency Act on December 11, 2023. The bipartisan legislation aims to address the pressing issue of rising healthcare costs by implementing crucial changes, particularly affecting employers sponsoring group health plans. Transparency in Coverage Regulations The bill codifies existing transparency in coverage regulations, requiring the posting of machine-readable files (MRF) and making certain cost information available. Notably, changes include specific timing for posting the MRF, scheduled for the 10th day of each month. If enacted, this provision would come into effect for the first… Read More

Continue Reading